A 55-year-old man with type 2 diabetes, CKD Stage 3b (eGFR 38 mL/min), and ACE inhibitor + MRA therapy develops hyperkalemia (K+ 6.2 mEq/L). After dietary restriction and optimizing diuretics, potassium remains elevated. Which novel agent is most appropriate to manage hyperkalemia and allow continued RAASi therapy?

• A Patiromer (potassium-binding polymer) ✓
• B Sodium polystyrene sulfonate (kayexalate)
• C Furosemide dose escalation
• D Sodium bicarbonate supplementation

Explanation

Patiromer (calcium-exchange polymer) and sodium zirconium cyclosilicate (SZC) are newer potassium binders approved for hyperkalemia management in CKD. They are superior to sodium polystyrene sulfonate (kayexalate), which has delayed onset, GI side effects, and risk of colonic necrosis. Patiromer acts in the colon, exchanging calcium for potassium, and is specifically studied to allow continued RAASi/MRA therapy (AMBER trial). This is important in diabetic nephropathy where RAASi is nephroprotective. Furosemide addresses volume but not chronic hyperkalemia in CKD.

Reference: Harrison's Principles of Internal Medicine, 21st ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.